title: Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy.
abstract: Current cancer therapies are challenged by weakly soluble drugs and by drug combinations that exhibit non-uniform biodistribution and poor bioavailability. In this study, we have presented a new platform of advanced healthcare materials based on albumin nanoparticles (ANPs) engineered as tumor penetrating, delivery vehicles of combinatorially applied factors to solid tumors. These materials were designed to overcome three sequential key barriers: tissue level transport across solid tumor matrix; uptake kinetics into individual cancer cells; therapeutic resistance to single chemotherapeutic drugs. The ANPs were designed to penetrate deeper into solid tumor matrices using collagenase decoration and evaluated using a three-dimensional multicellular melanoma tumor spheroid model. Collagenase modified ANPs exhibited 1-2 orders of magnitude greater tumor penetration than unmodified ANPs into the spheroid mass after 96 hours, and showed preferential uptake into individual cancer cells for smaller sized ANPs (<100 nm). For enhanced efficacy, collagenase coated ANPs were modified with two therapeutic agents, curcumin and riluzole, with complementary mechanisms of action for combined cell cycle arrest and apoptosis in melanoma. The collagenase coated, drug loaded nanoparticles induced significantly more cell death within 3-D tumor models than the unmodified, dual drug loaded ANP particles and the kinetics of cytotoxicity was further influenced by the ANP size. Thus, multifunctional nanoparticles can be imbued with complementary size and protease activity features that allow them to penetrate solid tumors and deliver combinatorial therapeutic payload with enhanced cancer cytotoxicity but minimal collateral damage to healthy primary cells.
authors.affiliation: Department of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA.
authors.forename: Mingjie
authors.initials: M
authors.lastname: Cui
authors.forename: Dominik J
authors.initials: DJ
authors.lastname: Naczynski
authors.forename: Margot
authors.initials: M
authors.lastname: Zevon
authors.forename: Craig K
authors.initials: CK
authors.lastname: Griffith
authors.forename: Larisa
authors.initials: L
authors.lastname: Sheihet
authors.forename: Izmarie
authors.initials: I
authors.lastname: Poventud-Fuentes
authors.forename: Suzie
authors.initials: S
authors.lastname: Chen
authors.forename: Charles M
authors.initials: CM
authors.lastname: Roth
authors.forename: Prabhas V
authors.initials: PV
authors.lastname: Moghe
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D017364:Collagenases / Q000378:metabolism; D003474:Curcumin / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity; D004337:Drug Carriers / Q000737:chemistry*; D006801:Humans; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D009369:Neoplasms / Q000188:drug therapy; D010316:Particle Size; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000737:chemistry / Q000235:genetics; D019782:Riluzole / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity; D012709:Serum Albumin / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D011994:Recombinant Proteins; D012709:Serum Albumin; D019782:Riluzole; D017364:Collagenases; D003474:Curcumin
keywords: albumin nanoparticles; collagenase; drug delivery; tumor penetration